President & Chief Executive Officer: Alan W. Milinazzo
Mr. Milinazzo brings more than two and a half decades of executive management experience in the life sciences sector. He spent 12 years as an executive with Boston Scientific Corporation in numerous executive roles, including Vice President of Marketing for SCIMED Europe. Mr. Milinazzo then served as Vice President of Medtronic Inc.’s Vascular business, as well as, Vice President and General Manager of Medtronic’s Coronary and Peripheral businesses. He was instrumental in the development and commercialization of a number of key products while at Medtronic, including the company’s first drug coated stent platform, Endeavor, which has generated over $1 billion in revenues since its launch. Most recently, Mr. Milinazzo served at Orthofix International in 2005 as Chief Operating Officer and succeeded to the position of Chief Executive Officer in April of 2006.
Mr. Milinazzo currently serves as a director of Flexion Therapeutics, Medpace and Trimedics and holds a bachelor’s degree, Cum Laude, from Boston College.
Chief Operating Officer: James J. Barry
Cheif Technology Officer: Eli Bar
|Eli Bar has over 15 years experience in medical device product development and more than seven years of experience as VP R&D in medical device companies. Mr. Bar has vast experience building a complete research and development structure; managing the team from the point of “an idea” to an advanced marketable product. He has been involved with many medical device projects over the years and has developed a synthetic vascular graft for femoral and coronary artery replacement, a covered stent, and a fully implantable VAD (Ventricular Assist Device). Mr. Bar has more than 9 filed device and method patents and he has initiated two medical device projects. Mr. Bar graduated from New Haven University, CT, with a B.Sc. of Mechanical Engineering.|
CFO: Craig Shore
|Mr. Shore has over 25 years of experience in financial management in the United States, Europe and Israel. He has served in various senior financial and general management roles at General Electric, Dunn and Bradstreet, Pfizer Pharmaceuticals and Bristol Myers Squibb. The vast majority of his career has been spent within the pharmaceutical and high tech industries. His experience includes raising capital both in the private and public markets. While serving as Chief Financial Officer of a leading telecom company, RIT Technologies, Mr. Shore successfully led its initial public offering on NASDAQ and subsequently managed all investor relations. Mr. Shore graduated with honors and received a B.Sc. in Finance from Pennsylvania State University and an M.B.A. from George Washington University. He strengthened his financial and leadership skills through the General Electric’s Financial Management Program.|
VP of Corporate Development: Gwen Bame
Ms. Bame has over twenty years of management experience in the medical device industry. In 1989 Ms. Bame began what would be a twelve year tenure with Boston Scientific, serving in several leadership positions in the interventional cardiology space, culminating in a strategic Corporate Account role. From 2001 until 2009, she served as Area Vice President Sales & Vice President of Corporate Accounts at Aspect Medical Systems before accepting an offer to serve as Zone Vice President at Covidien. Her experience includes contract negotiation, strategic partnership management, partner collaboration and a broad base of industry relationships. Ms. Bame is also an entrepreneur and earned her Bachelor of Arts in Business Administration from Washington State University.
CMO: Chaim Lotan MD, FACC, FESC
|Professor Lotan is the Head of The Heart Institute of the Hadassah University Medical Center. Prof. Lotan is the Chairman of the Ministry of Health Committee for Certification & Licensing of Coronary Stents in the Israel and has been in addition the principle investigator in many of the leading studies in interventional cardiology and coronary stents, with many publications in this field. As a prominent figure in the world of interventional cardiology, Prof. Lotan has been invited as a faculty member and a much appreciated lecturer to many of the leading interventional meetings and is one of the leading directors of the yearly international meeting of “Innovation in Cardiovascular Intervention.”|
VP of Global Marketing & Strategy: David Blossom
|Mr. Blossom has over 20 years of sales and marketing experience in interventional medical devices. He worked for 5 years at Procter & Gamble Corporation before moving onto Boston Scientific Corporation in several senior sales and marketing roles within the vascular division for over 8 years. During his tenure with Boston Scientific Vascular, he was responsible globally for the venous disease/vena cava filter product line, which ultimately became the market leader in this highly competitive product category. After Boston Scientific, David co-founded a start up company and later joined Covidien/Aspect Medical Systems in various senior marketing roles. At Covidien/Aspect Medical Systems, he successfully contributed to the company’s growth from a $20 million annual revenue business to $110 million resulting in an acquisition from Covidien. Prior to joining InspireMD, Mr. Blossom served as Executive Vice President of Coronary Business at Cappella Medical Systems where he worked with Cardiologists around the world developing solutions for the treatment of complex coronary artery disease. Mr. Blossom earned his Bachelors degree from New Mexico State University and Masters degree from Louisiana State University.||
Vice President Global Sales Operations: Rick Olson
|Mr. Olson is a 25-year global sales, marketing and management executive with expertise in developing and executing strategies to achieve scalable growth for an array of novel medical device technology companies, including Boston Scientific and Covidien. Prior to joining InspireMD, Mr. Olson served as the Director of International Strategy and HPMS (High Performance Management System) at Covidien. Before it was acquired by Covidien, Mr. Olson was Director of International Neurovascular Marketing & Sales Force Development at ev3, Inc., where he initiated market development and sales execution strategies for all OUS markets. During his tenure with ev3, revenues increased from less than $5 million to over $400 million in sales leading up to the acquisition of ev3 by Covidien in 2008. Prior to that, Mr. Olson spent nine years at Boston Scientific where he served in various sales and marketing leadership positions both in Europe and the United States. Mr. Olson holds a Bachelor’s Degree in Psychology from Oregon State University.||